(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 472.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.66%.
X4 Pharmaceuticals's revenue in 2024 is $563,000.On average, 6 Wall Street analysts forecast XFOR's revenue for 2024 to be $1,097,774,334, with the lowest XFOR revenue forecast at $421,248,785, and the highest XFOR revenue forecast at $2,308,443,342. On average, 6 Wall Street analysts forecast XFOR's revenue for 2025 to be $7,876,509,782, with the lowest XFOR revenue forecast at $1,572,100,466, and the highest XFOR revenue forecast at $23,707,881,620.
In 2026, XFOR is forecast to generate $18,544,045,514 in revenue, with the lowest revenue forecast at $3,779,444,099 and the highest revenue forecast at $40,237,683,943.